Abstract
In vitro susceptibility study of nosocomial strains of Pseudomonas aeruginosa isolated from patients with nosocomial infections in 21 Russian ICUs was performed. Antibiotics with antipseudomonal activity, such as piperacillin, piperacillin/tazobactam, ceftazidime, imipenem, meropenem, gentamicin, amikacin, ciprofloxacin were tested. The most active against tested P. aeruginosa isolates were meropenem, amikacin, ceftazidime. Rates of non-susceptibility to these antimicrobial agents were 3.0, 6.3 and 12.2%, respectively. The less active antibiotics were imipenem and ciprofloxacin, to which rates of non-susceptibility were 22.9 and 32.8, respectively. The least active antipseudomonal drug was gentamicin; 73.9% of tested P. aeruginosa isolates were non-susceptible. In this study, rates of non-susceptibility of P. aeruginosa to piperacillin and piperacillin/tazobactam were 56.5 and 37.7%, respectively.
-
1.
Stratchounski L., Reshedko G., Stetsiouk O., Kretchi-kova O., Riabkova E. Results of Russian country-widesurveillance of antimicrobial resistance of nosocomialgram-negative bacteria (NGNB) from 28 intensive careunits (ISUs). Proceedings of the 41st InterscienceConference on Antimicrobial Agents and Chemotherapy;2001 Sep–Dec, Chicago, USA. p. 113.
-
2.
Harris A., Torres-Viera C., Venkataraman L., DeGiro-lami P., Samore M., Carmeli Y. Epidemiology and clinicaloutcomes of patients with multiresistantPseudomonasaeruginosa.Clin Infect Dis 1999; 28:1028-33.
-
3.
NCCLS Performance Standards for AntimicrobialSusceptibility Testing; Eleventh InformationalSupplement, M100-S11, 2001; 21(1).
-
4.
Bronzwaer S.L.A.M., Goettsch W., Ollson-Liljequist B.,Weil M.C.J., Vatopoulos A.C., Sprenger M.J.W.European Antimicrobial Resistance Surveillance System(EARSS): objectives and organization. Eurosurveillance.1999; 4:4:41.
-
5.
Gales A.C., Jones R.N., Turnidge J., Rennie R., Ramphal R.Characterization ofPseudomonas aeruginosaisolates:occurrence rates, antimicrobial susceptibility patterns,and molecular typing in the Global SENTRY antimicro-bial surveillance program, 1997–1999. Clin Infect Dis2002; 32 (Suppl 2): S146-55.
-
6.
Garcia-Rodriguez J.A., Jones R.N., and the MYSTICProgramme Study Group. Antimicrobial resistance ingram-negative isolates from European intensive careunits: data from the Meropenem Yearly SusceptibilityTest Information Collection (MYSTIC) program.J Chemother 2002; 14: 25-32.
-
7.
Mutnick A., Rhomberg P., Jones R.N. Carbapenem resis-tance in Enteric bacilli andP. aeruginosain the USA(1999–2002): report from the MYSTIC program.Proceedings of the 42nd Interscience Conference onAntimicrobial Agents and Chemotherapy; 2002 Sep27–30, San Diego, USA. p. 90.
-
8.
Sahm D.F., Draghi D.C., Master R.N., Thornsberry C.,Jones M.E., Karlowsky J.A., Critchley I.A.Pseudomonasaeruginosaantimicrobial resistance update: U.S. resis-tance trends from 1998 to 2001. Proceedings of the42nd Interscience Conference on Antimicrobial Agentsand Chemotherapy; 2002 Sep 27–30, San Diego, USA.p. 91.
-
9.
Livermore D.M. Multiple mechanisms of antimicrobialresistance inPseudomonas aeruginosa: our worst night-mare? Clin Infect Dis 2002; 34:634-40.
-
10.
Senda K., Arakawa Y., Nakashima K., et al. Multifocaloutbreaks of metallo-β-lactamase-producingPseudomonas aeruginosaresistant to broad-spectrumβ-lactams,including carbapenems. Antimicrob Agents Chemother1996; 40:349-53.
-
11.
Cornaglia G., Mazzariol A., Lauretti L., Rossolini G.M.,Fontana R. Hospital outbreak of carbapenem-resistantPseudomonas aeruginosaproducing VIM-I, a novel trans-ferable metallo-β-lactamase. Clin Infect Dis 2000;31:1119-25.
-
12.
Nordmann P., Poirel L. Emerging carbapenemases inGram-negative aerobes. Clin Microbiol Infect 2002;8:321-31.
-
13.
Masuda N., Sakagawa E., Ohya S., Gotoh N., Tsujimo-to H., Nishino T. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumpsinPseudomonas aeruginosa.Antimicrob AgentsChemother 2000; 44:3327-37.
-
14.
Stratchounski L.S., Kozlov R.S., Reshedko G.K., Ste-tsiouk O.U., Chavrikova E.P. Antimicrobial resistancepatterns among aerobic gram-negative bacilli isolatedfrom patients in Intensive Care Units: results of multi-centre study in Russia. Clin Microbiol Infect 1998;4:497-507.
-
15.
Carmeli Y., Troillet N., Eliopoulos G.M., Samore M.H.Emergence of Antibiotic-ResistantPseudomonas aeruginosa:comparison of risks associated with differentantipseudomonal agents. Antimicrob Agents Chemother1999; 43:1379-82.
-
16.
Harris A.D, Smith D, Johnson J.A., Bradham D.D.,Roghmann M. Risk factors for imipenem-resistantPseudomonas aeruginosaamong hospitalized patients.Clin Infect Dis 2002; 34:340-5.
-
17.
Harris A.D., Perencevich E., Roghmann M., Morris G.,Kaye K.S., Johnson J.A. Risk factors for pipe-racillin/tazobactam-resistantPseudomonas aeruginosaamong hospitalized patients. Antimicrob AgentsChemother 2002; 46:854-8.
-
18.
Stephen J., Mutnick A., Jones R.N. Assessment of patho-gens and resistance patterns among intensive care unit(ICU) patients in North America: initial report from theSENTRY antimicrobial surveillance program (2001).Proceedings of the 42nd Interscience Conference onAntimicrobial Agents and Chemotherapy; 2002 Sep27–30, San Diego, USA. p. 89.
-
19.
Jalal S., Wretlind B. Mechanisms of quinolone resistancein clinical strains ofPseudomonas aeruginosa.MicrobDrug Resist 1998; 4:257-61.
-
20.
Nakano M., Deguchi T., Kawamura T., et al. Mutation inthegyrAandparCgenes in fluoroquinolone-resistantclinical isolates ofPseudomonas aeruginosa. AntimicrobAgents Chemother 1997; 41:2289-91.
-
21.
Schmitz F.-J., Verhoef J., Fluit A.C, and the SENTRYParticipants Group. Prevalence of aminoglycoside resis-tance in 20 European University hospitals participatingin the European SENTRY antimicrobial surveillanceprogramme. Eur J Clin Microbiol Infect Dis 1999;18:414-21.
-
22.
Coleman K., et al. Bacterial resistance mechanisms astherapeutic targets. J Antimicrob Chemother 1994;33:1091-116.
-
23.
Решедько Г.К. Механизмы резистентности к амино-гликозидам у нозокомиальных грамотрицательныхбактерий в России: результаты многоцентрового ис-следования. Клин микробиол антимикроб химиотер2001; 3:111-25.
-
24.
Miller G.H., aminoglycoside resistance study groups.Resistance to aminoglycosides inPseudomonas. Trends inMicrobiol 1994; 2:347-53.